A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

Our study found that doing these kinds of screenings on patients doesn't make any marked difference in their long-term survival rates." J. Brent Muhlestein, principal investigator of the study and ...

LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...

Discover reliable and free data sources to enhance your SEO content strategy. Build authority and credibility with accurate and trustworthy data. The internet is awash in an endless stream of ...

Here's why it made the list ...

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years.

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic ...

Oncology trials often celebrate treatments improving progression-free survival, yet toxicity-related censoring can bias ...

The 2-year progression free survival was improved with the addition of toripalimab (92·0% [95% CI 86·7–97·3]) compared with placebo (74·0% [61·8–86·2]; stratified hazard ratio 0·40 [95% CI 0·18–0·89]; ...

A Giant Structure in Space Challenges Our Understanding of The Universe Why Star Trek: Enterprise Had A Different Title For Its First Two Seasons Helpful Tips For A Growing A Thriving Thanksgiving ...

And yet, only last week it was the Pacific leaders at CHOGM and the UN Secretary-General conveying how survival of planetary life depends on decisions made now. With UNCOP 29 in Baku, Azerbaijan ...